{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:58Z","timestamp":1761710158155,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171339"],"award-info":[{"award-number":["82171339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2022ZDLSF02-04"],"award-info":[{"award-number":["2022ZDLSF02-04"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Youth Innovation Team of Shaanxi Universities","award":["2023-997-71"],"award-info":[{"award-number":["2023-997-71"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the efficacy and safety of low-dose rituximab (RTX) strategy in patients with neuromyelitis optica spectrum disorder (NMOSD) over a period exceeding 5 years and to investigate the impact of treatment compliance on clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective analysis of 81 NMOSD patients who received low-dose RTX at Tangdu Hospital from January 2014 to December 2019. The treatment protocol involved an induction phase of 100\u00a0mg weekly for three weeks, followed by maintenance doses of 100\u00a0mg every six months. Demographic characteristics, the expanded disability status scale (EDSS) scores, annualized relapse rates (ARR), number and date of attacks, and adverse events were collected. The influence of compliance on treatment efficacy was assessed using multivariable Cox regression and propensity score-weighted analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Over the follow-up period, 32.1% of patients experienced relapses, with the ARR significantly reduced from a median of 1.5 before treatment to 0 after RTX therapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). EDSS scores improved significantly from a median of 3.5 to 1.5 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The relapse rate was significantly lower in the good compliance group compared to the poor compliance group (9.5% vs. 56.4%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and good compliance was associated with a reduced risk of relapse (HR 0.07; 95% CI 0.02\u20130.25, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). A total of 19 patients (23.5%) experienced mild adverse events, with no serious adverse events reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings support the long-term efficacy and safety of low-dose RTX strategy in treating NMOSD, highlighting the crucial role of treatment compliance in achieving favorable clinical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03770-9","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:35:21Z","timestamp":1748003721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term efficacy and safety of low-dose rituximab strategy in neuromyelitis optica spectrum disorder: a retrospective cohort study on treatment compliance and clinical outcomes"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1595-1994","authenticated-orcid":false,"given":"Yao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6678-2602","authenticated-orcid":false,"given":"Cong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonghao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4018-1075","authenticated-orcid":false,"given":"Daidi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-881X","authenticated-orcid":false,"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"3770_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","volume":"387","author":"S Jarius","year":"2022","unstructured":"Jarius S, Aktas O, Ayzenberg I, et al. Neuromyelitis Optica spectrum disorder. N Engl J Med. 2022;387:631\u20139. https:\/\/doi.org\/10.1056\/NEJMra1904655","journal-title":"N Engl J Med"},{"key":"3770_CR2","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis Optica: distinction from multiple sclerosis. Lancet. 2004;364:2106\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet"},{"key":"3770_CR3","doi-asserted-by":"publisher","first-page":"e200124","DOI":"10.1212\/NXI.0000000000200124","volume":"10","author":"F Paul","year":"2023","unstructured":"Paul F, Marignier R, Palace J, et al. International Delphi consensus on the management of AQP4-IgG\u2009+\u2009NMOSD. Neurol Neuroimmunol Neuroinflammation. 2023;10:e200124. https:\/\/doi.org\/10.1212\/NXI.0000000000200124","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"3770_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis Optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19:298\u2013306. https:\/\/doi.org\/10.1016\/S1474-4422(20)30066-1","journal-title":"Lancet Neurol"},{"key":"3770_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis Optica spectrum disorders (NMOSD)\u2013 revised recommendations of the neuromyelitis Optica study group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271:141\u201376. https:\/\/doi.org\/10.1007\/s00415-023-11910-z","journal-title":"J Neurol"},{"key":"3770_CR6","doi-asserted-by":"publisher","first-page":"102683","DOI":"10.1016\/j.msard.2020.102683","volume":"48","author":"EP Correa-D\u00edaz","year":"2021","unstructured":"Correa-D\u00edaz EP, Torres-Herr\u00e1n GE, Mi\u00f1o Zambrano JE, et al. Impact of rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis Optica spectrum disorders. Mult Scler Relat Disord. 2021;48:102683. https:\/\/doi.org\/10.1016\/j.msard.2020.102683","journal-title":"Mult Scler Relat Disord"},{"key":"3770_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.4103\/aian.AIAN_167_21","volume":"24","author":"VA Patil","year":"2021","unstructured":"Patil VA, Kamat SN, Lalkaka JA, Singhal B. Efficacy and safety of rituximab in central nervous system demyelinating disorders. Ann Indian Acad Neurol. 2021;24:732\u20139. https:\/\/doi.org\/10.4103\/aian.AIAN_167_21","journal-title":"Ann Indian Acad Neurol"},{"key":"3770_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","volume":"266","author":"V Shaygannejad","year":"2019","unstructured":"Shaygannejad V, Fayyazi E, Badihian S, et al. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis Optica spectrum disorder: a prospective study. J Neurol. 2019;266:642\u201350. https:\/\/doi.org\/10.1007\/s00415-019-09180-9","journal-title":"J Neurol"},{"key":"3770_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","volume":"265","author":"P Cabre","year":"2018","unstructured":"Cabre P, Mejdoubi M, Jeannin S, et al. Treatment of neuromyelitis Optica with rituximab: a 2-year prospective multicenter study. J Neurol. 2018;265:917\u201325. https:\/\/doi.org\/10.1007\/s00415-018-8771-5","journal-title":"J Neurol"},{"key":"3770_CR29","doi-asserted-by":"publisher","unstructured":"Rindi LV, Za\u00e7e D, Braccialarghe N, et al. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis. Drug Saf. 2024; 47:333\u2013354. https:\/\/doi.org\/10.1007\/s40264-023-01383-4","DOI":"10.1007\/s40264-023-01383-4"},{"key":"3770_CR10","doi-asserted-by":"publisher","first-page":"1148632","DOI":"10.3389\/fimmu.2023.1148632","volume":"14","author":"D Zhao","year":"2023","unstructured":"Zhao D, Ren K, Lu J, et al. Rituximab at lower dose for neuromyelitis Optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study. Front Immunol. 2023;14:1148632. https:\/\/doi.org\/10.3389\/fimmu.2023.1148632","journal-title":"Front Immunol"},{"key":"3770_CR11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis Optica. Neurology. 2006;66:1485\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000216139.44259.74","journal-title":"Neurology"},{"key":"3770_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis Optica spectrum disorders. Neurology. 2015;85:177\u201389. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"3770_CR13","doi-asserted-by":"publisher","first-page":"105868","DOI":"10.1016\/j.msard.2024.105868","volume":"91","author":"RB Rocha","year":"2024","unstructured":"Rocha RB, Bomtempo FF, Tadinac ACB, et al. Heterogenous relapse and efficacy endpoint definitions for neuromyelitis Optica spectrum disorder studies: A systematic review. Mult Scler Relat Disord. 2024;91:105868. https:\/\/doi.org\/10.1016\/j.msard.2024.105868","journal-title":"Mult Scler Relat Disord"},{"key":"3770_CR14","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1212\/WNL.0000000000207443","volume":"101","author":"S Demuth","year":"2023","unstructured":"Demuth S, Collongues N, Audoin B, et al. Rituximab De-escalation in patients with neuromyelitis Optica spectrum disorder. Neurology. 2023;101:e438\u201350. https:\/\/doi.org\/10.1212\/WNL.0000000000207443","journal-title":"Neurology"},{"key":"3770_CR15","doi-asserted-by":"publisher","first-page":"1458556","DOI":"10.3389\/fimmu.2024.1458556","volume":"15","author":"B Xue","year":"2024","unstructured":"Xue B, Li J, Xie D, et al. Effects of early intervention in neuromyelitis Optica spectrum disorder patients with seropositive AQP4 antibodies. Front Immunol. 2024;15:1458556. https:\/\/doi.org\/10.3389\/fimmu.2024.1458556","journal-title":"Front Immunol"},{"key":"3770_CR16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/jnnp-2022-330714","volume":"94","author":"SY Park","year":"2023","unstructured":"Park SY, Kwon YN, Kim S, et al. Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis Optica spectrum. J Neurol Neurosurg Psychiatry. 2023;94:800\u20135. https:\/\/doi.org\/10.1136\/jnnp-2022-330714","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3770_CR17","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"S-H Kim","year":"2013","unstructured":"Kim S-H, Huh S-Y, Lee SJ, et al. A 5-Year Follow-up of rituximab treatment in patients with neuromyelitis Optica spectrum disorder. JAMA Neurol. 2013;70:1110. https:\/\/doi.org\/10.1001\/jamaneurol.2013.3071","journal-title":"JAMA Neurol"},{"key":"3770_CR18","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BAC Cree","year":"2005","unstructured":"Cree BAC, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis Optica. Neurology. 2005;64:1270\u20132. https:\/\/doi.org\/10.1212\/01.WNL.0000159399.81861.D5","journal-title":"Neurology"},{"key":"3770_CR19","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis Optica spectrum disorders. JAMA Neurol. 2016;73:1342. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1637","journal-title":"JAMA Neurol"},{"key":"3770_CR20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"C-S Yang","year":"2013","unstructured":"Yang C-S, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis Optica. Neurology. 2013;81:710\u20133. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a1aac7","journal-title":"Neurology"},{"key":"3770_CR21","doi-asserted-by":"publisher","first-page":"578285","DOI":"10.1016\/j.jneuroim.2024.578285","volume":"387","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu R, Gao B, et al. Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis Optica spectrum disorder. J Neuroimmunol. 2024;387:578285. https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578285","journal-title":"J Neuroimmunol"},{"key":"3770_CR22","doi-asserted-by":"publisher","first-page":"891064","DOI":"10.3389\/fneur.2022.891064","volume":"13","author":"J Lin","year":"2022","unstructured":"Lin J, Xue B, Li J, et al. Comparison of Long-Term use of low dose rituximab and mycophenolate mofetil in Chinese patients with neuromyelitis Optica spectrum disorder. Front Neurol. 2022;13:891064. https:\/\/doi.org\/10.3389\/fneur.2022.891064","journal-title":"Front Neurol"},{"key":"3770_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","volume":"316","author":"T Li","year":"2018","unstructured":"Li T, Zhang L-J, Zhang Q-X, et al. Anti-Rituximab antibody in patients with NMOSDs treated with low dose rituximab. J Neuroimmunol. 2018;316:107\u201311. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.021","journal-title":"J Neuroimmunol"},{"key":"3770_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","volume":"117","author":"M Zhang","year":"2017","unstructured":"Zhang M, Zhang C, Bai P, et al. Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis Optica: an over 2-year follow-up study. Acta Neurol Belg. 2017;117:695\u2013702. https:\/\/doi.org\/10.1007\/s13760-017-0795-6","journal-title":"Acta Neurol Belg"},{"key":"3770_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/jns.12653","volume":"29","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Sun C, Zhao Y, et al. Long-term and low\u2010dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2024;29:350\u20135. https:\/\/doi.org\/10.1111\/jns.12653","journal-title":"J Peripher Nerv Syst"},{"key":"3770_CR26","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s10067-019-04443-2","volume":"38","author":"Y Takakuwa","year":"2019","unstructured":"Takakuwa Y, Hanaoka H, Kiyokawa T, et al. Low-dose rituximab as induction therapy for ANCA-associated vasculitis. Clin Rheumatol. 2019;38:1217\u201323. https:\/\/doi.org\/10.1007\/s10067-019-04443-2","journal-title":"Clin Rheumatol"},{"key":"3770_CR27","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41598-024-53838-y","volume":"14","author":"T Ongphichetmetha","year":"2024","unstructured":"Ongphichetmetha T, Jitprapaikulsan J, Siritho S, et al. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis Optica spectrum disorder. Sci Rep. 2024;14:3503. https:\/\/doi.org\/10.1038\/s41598-024-53838-y","journal-title":"Sci Rep"},{"key":"3770_CR28","doi-asserted-by":"publisher","first-page":"104127","DOI":"10.1016\/j.msard.2022.104127","volume":"68","author":"K Wei","year":"2022","unstructured":"Wei K, Nie Q, Zhu Y, et al. Different doses of rituximab for the therapy of neuromyelitis Optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Relat Disord. 2022;68:104127. https:\/\/doi.org\/10.1016\/j.msard.2022.104127","journal-title":"Mult Scler Relat Disord"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03770-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03770-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03770-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:35:23Z","timestamp":1748003723000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03770-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3770"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03770-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Helsinki Declaration of 1964, including its subsequent amendments. This study was approved by the Ethics Committees of Tangdu Hospital, Air Force Medical University (Fourth Military Medical University) (No. K202212-12).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}